Medicare Part B Lab Test Spending Rises 5% in 2024, Driven by Genetic Tests
Genetic tests accounted for 43% of all Part B lab spending despite representing only 5% of tests performed, according to HHS OIG data.
Latest Articles
Editor's Top Picks
Three-Year NHS Study Shows Blood Test Reduces Stage IV Cancer Diagnoses
The Galleri blood test demonstrated a four-fold increase in cancer detection rates and substantial reduction in stage IV cancer diagnoses in 142,000 participants.
Be the First to Know What’s Next in the Lab
Every week, we dig into the biggest shifts, breakthroughs, and tech transforming clinical diagnostics. Straightforward, insightful, and always relevant.Critical Resources
Diagnostic Innovations
Illumina Announces NovaSeq X Performance Upgrades Including Q70 Quality Scores
Illumina has announced an 18-month roadmap for NovaSeq X, featuring a 40% output increase to 35 billion reads, faster turnaround times, new flow cell options, and the introduction of Q70 quality scores.
Equipment & Supply Spotlight
SPT Labtech Partners to Develop Automated Genomics Platform for Smaller Labs
The collaboration aims to develop an automated genomics platform for decentralized labs, aiming to expand access to streamlined NGS workflows in oncology.
News, Know-How & Standards
Disease Detection & Understanding
Veracyte Presents 15 Studies on Decipher Cancer Tests at ASCO GU Symposium
Veracyte will present over 15 studies on its Decipher prostate and bladder cancer tests, including new clinical trial data, at the 2026 ASCO Genitourinary Cancers Symposium in San Francisco.
